Cencora, Inc. (COR)
Cencora Earnings Review: The Selloff Was Overdone In My View
Cencora reported Q2 results with 3.8% revenue growth and a 129% EPS increase, but shares fell sharply, apparently due to a revenue miss. Despite a forward P/E of ~14 and manageable debt, COR faces thin margins, client concentration risks, and headwinds from biosimilars and drug price reductions. Management remains confident, targeting $3B in free cash flow and $1B in share repurchases for 2026, with ongoing M&A to expand specialty services.
Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
COR Stock Falls on Q2 Earnings & Revenue Miss, FY26 EPS View Raised
Cencora shares sink after Q2 earnings and revenues miss estimates, even as the company raises its fiscal 2026 EPS outlook.
Cencora (COR) Misses Q2 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $4.75 per share, missing the Zacks Consensus Estimate of $4.8 per share. This compares to earnings of $4.42 per share a year ago.
Seeking Clues to Cencora (COR) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside
Cencora (COR) gets its prior buy rating from 2025 reaffirmed, driven by several strong fundamentals, despite a recent price retreat. The healthcare distributor has a global brand footprint, a key role in serving specific clinical needs, and profitability, despite thin margins. The dividend case is compelling, with proven 10 year growth across many market cycles, and a low payout ratio.
COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal
Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care market.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.
California Public Employees Retirement System Has $184.01 Million Stock Holdings in Cencora, Inc. $COR
California Public Employees Retirement System lowered its stake in Cencora, Inc. (NYSE: COR) by 13.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 588,788 shares of the company's stock after selling 93,334 shares during the quarter. California Public Employees Retirement
Chilton Investment Co. Inc. Purchases New Holdings in Cencora, Inc. $COR
Chilton Investment Co. Inc. acquired a new stake in shares of Cencora, Inc. (NYSE: COR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,468 shares of the company's stock, valued at approximately $459,000. Other hedge funds and other
Alliancebernstein L.P. Has $278.09 Million Stake in Cencora, Inc. $COR
Alliancebernstein L.P. lowered its position in Cencora, Inc. (NYSE: COR) by 21.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 889,802 shares of the company's stock after selling 244,496 shares during the period. Alliancebernstein L.P. owned 0.46% of Cencora worth
